newsfilter
← Latest News
GlobeNewswire·

CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update

- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - - Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in